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In patients with cystic ﬁbrosis (CF), the isolation of ﬁlamentous fungi, in particular Aspergillus spp. in the respiratory secretions is a common
occurrence. Most of these patients do not fulﬁl the clinical criteria for a diagnosis of allergic bronchopulmonary aspergillosis (ABPA). The clinical
relevance of ﬁlamentous fungi and whether antifungal therapy should be started in patients with persistent respiratory exacerbations who do not
respond to two or more courses of appropriate oral or intravenous antibiotics and in whom no other organisms are isolated from respiratory
secretions is a dilemma for the CF clinician. In this article, we review the epidemiology and clinical signiﬁcance of ﬁlamentous fungi in the non-
ABPA CF lung, with an emphasis on Aspergillus spp. colonisation (AC), the clinical relevance of Aspergillus spp. positive respiratory cultures and
the outcome following antifungal therapy in these patients.
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Cystic fibrosis (CF) is a genetic disease that affects over 8500
people in the UK and over two million people carry the gene that
causes CF. As a result of new therapies and more aggressive
antibiotic management, life expectancy for children born in this
decade is expected to be 50 years or more [1]. Patients usually die
early as a result of progressive lung disease caused by recurrent
and ultimately chronic respiratory infections. The condition is a
result of a mutation in the cystic fibrosis transmembrane regulator
gene on chromosome 7 which encodes a chloride channel.
Defective channel activity leads to thick, viscous secretions and
impaired mucociliary clearance in the lung [2]. This causes
trapping of mucus, colonisation with bacteria and fungi, and a
persistent inflammatory response in the airways. Patients are
prone to infection with common respiratory pathogens such as
Haemophilus influenzae or Staphylococcus aureus and in early
adulthood most have chronic Pseudomonas aeruginosa infec-
tion. The number of isolates of filamentous fungi increases with
age in CF patients [3]. It has been suggested that the widespread
use of broad-spectrum antibiotics has favoured the selection of
fungi such as Aspergillus spp. [4].
Aspergillus fumigatus is the most common mould reported
from the sputa of CF patients [5–7]. It is ubiquitous in the
environment; in soil, water and decomposing organic matter.
Inhalation of spores into the distal airways can lead to
colonisation, saprophytic involvement in those with chronic
lung conditions such as chronic obstructive pulmonary disease
and CF. In healthy individuals, spores are cleared by the
mucociliary escalator and phagocytosed by cells of the innate
immune system such as macrophages and neutrophils. However
in patients with CF, impaired mucociliary clearance, mucus
plugging and the ability of Aspergillus spp. to evade or interfere
with phagolysosome fusion and complement fixation can lead to
locally invasive or disseminated infection [8].
The role of Aspergillus spp. in the non-ABPA CF lung is
unclear, and its presence in the respiratory secretions of CF
patients may be asymptomatic or occur in the context of clinical
disease. Here, we review the evidence for filamentous fungi
causing respiratory infection and worsening lung disease in CF
patients.
2. Fungi and cystic fibrosis
The fungal kingdom comprises over 1,000,000 species. Of
these, only a small number of thermotolerant fungi, particularly
members of the genera Aspergillus spp. and Penicillium and
some yeasts are able to grow at body temperature and are able to
non-invasively colonise the airways. The genus Aspergillus spp.
alone comprises well over one hundred species and several can
cause infections in humans. Invasive aspergillosis and chronic
necrotizing pneumonia can occur, in immunocompromisedpatients but these are thought to be rare in CF. Most attention
has focussed on A. fumigatus because it is the principal cause of
ABPA. A. fumigatus contains a number of potent allergens that
stimulate the antigen presenting cells and T lymphocytes of the
adaptive immune system and cause a spectrum of hypersensitiv-
ity diseases including sinusitis, bronchitis and ABPA [8].
3. Allergic bronchopulmonary aspergillosis
ABPA is caused by a hypersensitivity reaction to antigens of
Aspergillus spp. in individuals with pre-existing lung disease
such as asthma and CF. This causes a local inflammatory
response which is T helper 2 CD4+ mediated, leading to the
production of immunoglobulin (IgG and IgE) specific to
Aspergillus spp. and the release of cytokines in the airways.
Persistent inflammation can result in bronchiectasis and fibrosis.
There are different diagnostic criteria for ABPA issued by the CF
Trust in the United Kingdom and the CF Foundation in the
United States making comparisons between studies from
different centres more difficult. CF patients with ABPA tend to
have higher rates of AC [8] and poorer lung function parameters
compared to those with A. fumigatus sensitisation only. Further
in-depth discussion of ABPA in CF patients is outside the scope
of this review and the interested reader is referred to a recent
extensive review on this topic [8].
4. Epidemiology of Aspergillus fumigatus
The isolation rate of Aspergillus spp. from CF respiratory
specimens varies widely from 6 to 58% in the reported literature
[3,5,9–18] and this is true for both, adult and paediatric patients,
and across different geographical areas of the UK, Europe and
North America. There are several possible explanations for this
observation. Most importantly, different sputum processing
protocols with regards to fungi across laboratories including
incubation temperatures, length of culture, media employed and
conventional versus molecular detection will influence the
detection rate [5,9,10,13,14,17]. Different sampling techniques
like cough swabs, spontaneous and induced sputum, and BAL
samples may affect A. fumigatus detection [3]. We compared
differences in A. fumigatus isolation between routine cough or
sputum samples and BAL.When comparing samples obtained by
BAL with sputum or cough swabs in children, Saunders et al.
found that A. fumigatuswas reported from only 19.5% of sputum
samples and 2.7% of cough swabs obtained within three months
of a positive BAL [3]. This suggests that routine respiratory
sampling in childrenmay significantly underestimate AC and this
merits validation in a larger study.
Molecular typing of A. fumigatus shows that more than one
genotype can be present in the sputa of a CF patient [6,19].
Cimon et al. [19] examined serial sputa from CF patients aged 11
to 20 years old and found that those patients who were newly
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eventually one genotype became predominant and was selected
over time in those who became chronically colonised. The
authors described four patterns of colonisation; (1) identical or
related genotypes were isolated over a long period of time
indicating that the patients were unable to clear the isolate, (2) one
predominant genotype that was not cleared from the airways,
(3) a succession of genotypes suggesting that clearance was
achieved but re-colonisation occurred from different isolates, and
(4) unique genotypes, found only once in a patient, which
suggested an ability to clear that isolate. The recurrence of the
same genotype over a period of time suggests an inability to clear
the fungus from the airways and this may be significant in the
pathogenesis of clinical disease.
A retrospective analysis of 1421 patients from 1985 to 2005
performed in adult patients cared for at the Royal Brompton
Hospital, London, UK found a significant decrease in AC from
18% to 9% [20]. The authors suggested that different antibiotic
practices compared with other centres may account for these
findings. In contrast, a recent Canadian CF registry cross-
sectional review comparing 3354 adult and paediatric patients
in 2005 with 3849 subjects in 2010 showed an increase in the
prevalence of Aspergillus spp. from 443 (13%) to 785 (20%)
[21]. These two studies demonstrate that the difficulties in
directly comparing data on Aspergillus spp. colonisation and
infection of the CF lung as local clinical and microbiological
practices and surveillance are likely to be different. Changes in
the airway microbiome over time, with Aspergillus spp. filling
the empty seats, a changing milieu at the level of the airway
surface but also frequency, type and administration route of
antibiotics and increased exposure over time have all been
suggested as potential factors in the increase of Aspergillus spp.
colonisation with increasing age. It is of course possible that
there are genuine differences in the prevalence of fungal
colonisation in patients from different geographical areas.
5. Laboratory processing
There are many different methods for the culture of
filamentous fungi. In the case of Aspergillus spp., these are
rapidly growing on almost any media and increasing the
incubation time beyond 48 h is unlikely to increase the yield.
However, the volume and dilution of sputum affects the
sensitivity of fungal detection and prolonging the incubation
period for up to four or six weeks increases the recovery of
slow growing fungi such as, for example, Exophiala spp. [22].
In the United Kingdom there are different national guidelines
in existence from the Health Protection Agency (HPA) [22] and
the CF Trust [4] for the culture of fungi from respiratory
secretions of CF patients. The UK CF Trust only recommends
that Sabouraud medium should be incubated up to ten days “at
the appropriate temperature”. The HPA advice is to incubate
homogenised and diluted whole sputum on Sabouraud agar at 30
and 35 °C, and the plate, to be read at 40 to 48 h with the option
of incubation up to six weeks for slow-growing fungi. Whilst this
is more specific, this is rarely done in a clinical laboratory setting.
In fact, laboratory techniques to identify other filamentous fungi,particularly slow growing ones, are not routinely established and
these are therefore rarely reported. New methods to increase
sensitivity of fungal culture are being explored. Pashley et al.
compared different dilutions of homogenised whole sputum and
neat plugs inoculated onto media and found that the rate of
detection of Aspergillus spp. was dependent on the volume and
dilution of sputum used and that the neat sputum plug was better
than homogenised diluted or whole sputum [23]. Different media
with novel combinations of antimicrobials may be superior in
detecting fungi compared to the traditionally used Sabouraud
dextrose agar [24]. This is an important area and more research is
probably needed before a standard can be recommended. Given
these controversies it is not surprising that a recent study by
Borman et al. found considerable differences in the processing
methods for CF samples in eight microbiology laboratories in
England (n=2) and France (n=6) [25]. Laboratories, all of which
serve tertiary CF services, differed in the volumes of sputum used
for examination, the culture media employed, incubation
temperature and length of incubation. Furthermore, variation
occurred in laboratories from the same geographical area that
served the same cohort of CF patients. The study reported a wide
variation in the isolation rates of positive samples for Aspergillus
spp. from 9 to 89% of patients and surmised that different
laboratory processing methods, at least to some extent, are likely
to be responsible for the wide variation observed. We recently
under took a survey ourselves, of laboratories serving paediatric
CF centres in the United Kingdom [Koo et al. 2011— personal
communication]. Between the 19 laboratories that participated in
the survey there was variation in the initial processing with lytic
agent, volume of sputa used to inoculate plates, type of media,
length of incubation and temperature, confirming the findings
reported by Borman et al. [25].
6. Antibacterial therapy and Aspergillus spp. colonisation
CF patients frequently receive broad-spectrum antibacterials
via a variety of routes including oral, intravenous and
increasingly nebulised, either as prophylaxis or for the treatment
of respiratory exacerbations. Several studies have highlighted the
association between nebulised antibacterials and Aspergillus spp.
isolation from the airway. A large multicentre, double-blind,
placebo-controlled trial of intermittent (month on, month off)
administration of nebulised tobramycin over a 24-week period,
involving 520 CF patients aged six years and older with
P. aeruginosa infection, found a significantly increased AC rate
in the tobramycin treated group [26]. A. fumigatus appears
rapidly after the initiation of this treatment as it was found in
sputum four weeks after the initiation of treatment in a separate
tobramycin versus colomycin comparison study [27]. Aspergillus
spp. were isolated more frequently in the tobramycin treated
group (5.7% versus 3.2%). The findings from these large clinical
trials are supported by two large retrospective cohort studies
[12,18] that investigated the association between AC and inhaled
antibacterial therapy. In the largest of these de Vrankijer et al.
reviewed the medical records and reports from respiratory
samples of 259 children and adults. In a multiple logistic
regression model the authors found that AC was independently
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correction for severity of lung disease (by correcting for FEV1)
[18]. This was also found in a large cohort of adult CF patients
where additionally AC was also associated with the use of
prophylactic oral antibiotics [12]. In contrast, a retrospective
study in French children found no association between
Aspergillus spp. isolation from the respiratory tract and inhaled
antibacterials [16]. However, it is interesting to note that an
increase in airway fungal isolation rates with age has been
reported by several studies [10,11,18] which may partly be due to
the nature of the respiratory specimens available for analysis.
Clearly, the relationship between antibiotic usage and AC is a
complex one that requires clarification. The selective pressure of
antibacterials may reduce competition and leave an unfilled niche
for Aspergillus spp. colonisation and infection. The type of
antibacterial and the method of administration may have different
effects on Aspergillus spp. acquisition. From the available
evidence, it does appear that inhaled antibiotic therapy,
particularly tobramycin, may be associated with an increase in
AC. It has to be stressed however that any potential clinical
implications of AC are largely unknown and would need to be
balanced with the beneficial effects of antibiotic therapy.
7. Pseudomonas infection and Aspergillus spp. colonisation
Studies investigating the association between Pseudomonas
and Aspergillus spp. colonisation and infection have yielded
conflicting results. A recent large retrospective review in
Canadian children with CF found a significant link between P.
aeruginosa and Aspergillus spp. respiratory infection [15] but this
has not been consistently reported in the literature [12,16–18].
Three studies reported from France [13,17,18] found no
significant association between Pseudomonas and Aspergillus
spp. isolation in either children or adults. Paugum et al. reviewed
657 sputum samples from 201 CF adults during a 24-month
period and whilst a higher rate of Pseudomonas colonisation was
present in patients with AC this was not statistically significant
(78.9% versus 68.9%, P=0.07) [17]. A recent large review of
Dutch adults and children with CF found an association between
AC and chronic P. aeruginosa infection on simple logistic
regression analysis that disappeared in a multiple logistic
regression model [18]. The authors also performed a longitudinal
analysis (over 4 years) splitting the study population into three
groups according to the duration of AC. They found no difference
in positive cultures for P. aeruginosa between the groups. The
authors concluded that important confounders may have
influenced these results. Patients with longer duration of
colonisation were older (Pb0.001), were more likely to use
inhaled antibiotics, (Pb0.001), had more hospitalisations (P=
0.02), lower FEV1 values (Pb0.001) and lower BMI Z-scores
(P=0.04). The results of these studies suggest that the
relationship between Pseudomonas and AC may partly be
explained by the age of the study population. Interestingly
however, there is in vitro evidence that on a molecular level
P. aeruginosa produces proteases that directly affect and damage
the respiratory epithelium and it has been suggested that this may
promote A. fumigatus sensitisation [28]. In vitro analysis ofculture filtrates of Aspergillus spp. from patients with invasive
aspergillosis shows a slowing of ciliary beat [28]. Other,
secondary metabolites produced by certain Gram-negative
bacteria including Pseudomonas spp. may change the airway
surface milieu and act as fungal growth inhibitors. Pyocyanin, a
toxin produced by P. aeruginosa has been shown, in vitro, to
inhibit growth of A. fumigatus and Candida spp. in a
dose-dependent manner [29]. The in vitro concentrations used
were relatively high (pyocyanin minimum inhibitory concentra-
tions for Candida albicans and A. fumigatus wereN64 μg/ml)
and it is not clear if such concentrations could be achieved
in vivo. The interaction between respiratory pathogens like
P. aeruginosa and filamentous fungi is likely to be a complex one
and this merits further study. Whether the presence of both
microorganisms simultaneously has a cumulative effect of
damaging respiratory epithelia in CF patients over time remains
to be shown.
8. Aspergillus spp. colonisation and severity of cystic
fibrosis lung disease
The key clinical question of course is whether Aspergillus spp.
cause respiratory disease in CF in their own right or if filamentous
fungi are no more than innocent bystanders. There are no
prospective studies to answer this question. A recent large
retrospective cohort study in Canadian children reported patient
data reviewed over a seven year period [15]. Aspergillus spp.
infection was defined as two or more positive sputum or BAL
samples in one year. Children with persistent Aspergillus spp.
infection had a lower FEV1% predicted over the study period
compared to uninfected children. In a regression model, children
with Aspergillus spp. infection had the greatest risk of pulmonary
exacerbations requiring hospitalisation (RR=1.94, P=0.0002)
which was independent of other factors. There was however a
very strong association between Aspergillus spp. infection and
Pseudomonas isolation in the study group.
In a study of 85 French children with a mean age of 8.5 years
and a mean observation period of six years [16] the authors
found no significant association between AC (defined as two or
more positive samples for Aspergillus spp. species over a
one-year period) and FEV1% predicted, body mass index or any
other measure of disease severity [16]. Similarly no link between
AC and lung disease severity was found in a similar study
reported by de Vrankijer et al., where AC was defined as the
presence of A. fumigatus in N50% of respiratory cultures in one
calendar year. AC was independently associated with increased
age and the use of inhaled antibiotics. Adjusted for confounders
like age and BMI Z score AC was not independently associated
with lung function decline although the authors report that AC
was found predominantly in those with more severe disease and
treatment burden [18]. Two older retrospective studies in
German [12] and French children [10] found no associations
between AC and clinical parameters like FEV1, Shwachman–
Kulczycki (S–K) scores and radiological scores of lung disease.
In contrast to these studies, two reports from US CF centres
reported lower S–K and higher chest radiograph scores in
patients who had Aspergillus spp. isolated from the airways
Table 1
Proposed definitions for Aspergillus spp. colonisation and infection.
Aspergillus spp. colonisation Aspergillus spp. infection
• Isolation of Aspergillus spp.
from 50% or more sputum
samples over six months
to one year
• No deterioration in lung
function
• No increase in respiratory
symptoms like cough
• Isolation of Aspergillus spp. from 50%
or more sputum samples over six
months to one year
• Decline in lung function parameters
• Respiratory exacerbation with
(increased) cough
• Aspergillus spp. the only organism
isolated from repeated sputum
samples
• No, or incomplete response to a two
to four week course of appropriate
broad spectrum antibiotics
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spp. group on the basis of a single isolate which does not
constitute colonisation and these studies are not directly
comparable to the more recent studies stipulating repeated
isolation for a diagnosis of AC.
It is important to highlight that the heterogeneity of study
designs with variable duration of study periods, the different
techniques of obtaining respiratory samples, varying definitions
of Aspergillus spp. colonisation and Aspergillus spp. infection
and different laboratory protocols make comparisons between
studies difficult.
All the published observational studies are retrospective and
from the available data we conclude that AC has been associated
with increasing age, co-infection with P. aeruginosa and the
prolonged use of oral and/or nebulised antibiotics. All these are
important confounders and as a result the isolated contribution of
Aspergillus spp. colonisation or infection of the airways on
progression of CF lung disease remains an unresolved question.9. The use of antifungal therapy is controversial in
non-ABPA CF patients
There is, to our knowledge, only one recently reported
Canadian multicentre randomised, placebo-controlled pilot studyTable 2
Summary of published studies using antifungal medication to treat Aspergillus spp.
Study Patients Inter
Hilliard et al. [32] n=21; median 11.3 (5–16) years.
Mixture of ABPA and non-ABPA subjects.
All c
for a
Shoseyov et al. [33] n=6; median 14 (10–30) years. Oral
to 2
iv A
Kanthan et al. [31] n=85;
1996 cohort; Af cases, n=19, median
age 13.66 (9.78–15.99) years; controls n=19,
median age 12.44 (9.02–14.96) years.
2001 cohort; Af cases n=24, median
age 12.58 (9.61–16) years; controls n=23,
median age 14.61 (12.68–15.29) years.
Obse
study
(199
Aaron et al. [30] n=35; enrolled patients 6 years and older,
mean age 25 years in both groups.
Oral
or plinvolving 35 non-ABPA CF adults and children [30]. Patients
over six years of age were selected if they were deemed to be
A. fumigatus colonised but clinically stable and free from acute
infection at the time of enrolment. A requirement for study entry
was two positive sputum cultures for A. fumigatus in the previous
year with one positive culture within the last four months
preceding enrolment. Subjects were randomised to daily oral
itraconazole or placebo for 24 weeks. There was no difference in
the rate of exacerbations requiring intravenous antibiotics over
the study period between the two groups which was the primary
outcome measure. There were also no differences in FEV1 or
quality of life measures between the groups. Adequate plasma
levels were achieved in only approximately half the patients. In
addition, itraconazole resistance has been demonstrated in vitro
for A. fumigatus but this was not tested. The study highlights the
difficulties encountered when dealing with A. fumigatus isolated
from CF sputum as it remains uncertain whether such a finding
constitutes simple colonisation with no impact on lung disease or
true respiratory infection. Based on the reviewed literature we
propose the following criteria for Aspergillus spp. colonisation
and infection which we have summarised in Table 1. Future
randomised, placebo-controlled trials based on these consider-
ations and using agents with a better oral bioavailability, such as
voriconazole, or a better pharmacokinetic profile would be
warranted.
Oral triazoles have been used in the treatment of pulmonary
exacerbations and reported in the form of either cohort studies or
case series without randomisation, particularly in patients with
repeated isolation of Aspergillus spp. in the absence of other
organisms where repeat courses of broad spectrum antibiotics
have failed to resolve the exacerbation. These studies have been
summarised in Table 2. Kanthan et al. retrospectively compared
two cohorts of children with CF sensitized to A. fumigatus over
two 5-year periods (1996–2000 and 2001–2005). Those in the
latter cohort had higher FEV1% predicted and this was attributed
to them receiving azole treatment more frequently than the earlier
cohort. The authors state that there were no significant differences
in treatment between the two cohorts with respect to oral
or inhaled corticosteroids, azithromycin, nebulised rhDNaserespiratory colonisation or infection in patients with CF.
vention Outcome
hildren received voriconazole
median of 22 (1–50) weeks.
Significant increase in FEV1 and
FVC over the study period in
ABPA subjects only.
itraconazole for 4 months up
years. One patient also received
mbisome.
All experienced some improvement
in clinical parameters, FEV1% predicted
improved in all but one.
rvational cross-sectional cohort
using two cohorts of patients
6–2000 and 2001–2005).
Patients in the 2001 cohort received
more antifungal therapy and had a
higher FEV1% predicted compared
to the 1996 cohort.
itraconazole for 24 weeks
acebo.
No difference in exacerbation rates,
FEV1% predicted or QOL between
the two groups.
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comparing cohorts from different time points is problematic
particularly as approximately half of the subjects with A. fumigatus
sensitisation also had ABPA. The authors did not report whether
there were any differences in outcome between ABPA and
non-ABPA, presumably due to small numbers to begin with. A
further retrospective case review of 21 children treated with
voriconazole (13 of who fulfilled ABPA criteria) found clinical
improvement in patients with ABPA but no significant changes in
FEV1% predicted in those without ABPA. Furthermore, some
children who fulfilled ABPA criteria were additionally prescribed
immune-modulatory therapy [32]. Finally, a small case series (n=
6) of CF children with respiratory deterioration and positive
sputum culture for A. fumigatus, who did not fulfil ABPA criteria,
reported variable clinical improvement in all patients treated
with anti-fungal agents [33]. Treatment was given for up to two
years and not all children showed improvements in respiratory
function.
9.1. Brief summary of treatment options
Three oral drugs are available with activity against Aspergillus
spp., itraconazole, voriconazole and posaconazole. These agents
vary with regards to their pharmacokinetic and pharmacodynamic
properties, side effect profiles, cost and in rates of resistance.
Itraconazole and voriconazole have been used more extensively
than posaconazole in the CF population. Therapeutic drug
monitoring is recommended for all three agents due to poor
bioavailabilty with itraconazole and to a lesser extent posaconazole
and the highly variable metabolism of voriconazole, especially in
children. Resistance to all triazoles is growing but this is especially
a problem with itraconazole where N20% resistance has been
reported. This may preclude their use in the not too distant future.
Intravenous agents available with activity against Aspergillus spp.
include conventional and lipid formulations (e.g. Ambisome) of
amphotericin B and the echinocandins which include caspofungin
and micafungin. Ambisome and caspofungin have been used
in CF patients post transplant for the treatment of invasive
aspergillosis but experience in the treatment of airway colonisation
or infection is very limited. Aerosolised amphotericin B and lipid
formulation of this agent have been used in adult and paediatric CF
patients with ABPA.
10. Conclusion
The contribution of fungal infection to the progressive
deterioration of respiratory function in CF is controversial.
Whether, or when, isolation of Aspergillus spp. from the lower
respiratory tract of patients with CF represents harmless
colonisation or active infection is not well understood. The
evidence so far is largely anecdotal and derived from retrospec-
tive, often small case series and does not allow firm conclusions
as to whether anti-fungal treatment is justified, and if so, who
should be treated and for how long. A recent randomised, placebo
controlled trial in CF patients with A. fumigatus airway
colonisation found no benefits of antifungal treatment with
respect to exacerbations or lung function.The lack of standardisation of laboratory detection methods
and differences in the nature of respiratory samples make
interpretation of the published data difficult. Antifungal therapy
is expensive and not without risks of significant side-effects.
The clinical implication of Aspergillus spp. isolation from
sputum needs to be studied prospectively based on robust
national and international protocols for the processing of CF
sputum samples for fungi. Finally and importantly there needs
to be a consensus on what likely constitutes Aspergillus spp.
infection warranting specific treatment which would pave the
way for an appropriately powered randomised placebo
controlled trial in order to conclusively establish the potential
benefits of antifungal therapy in such patients.Role of funding source
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